+

WO2011009849A2 - Procédé pour la préparation d'esters d'hydroxyacides optiquement actifs - Google Patents

Procédé pour la préparation d'esters d'hydroxyacides optiquement actifs Download PDF

Info

Publication number
WO2011009849A2
WO2011009849A2 PCT/EP2010/060458 EP2010060458W WO2011009849A2 WO 2011009849 A2 WO2011009849 A2 WO 2011009849A2 EP 2010060458 W EP2010060458 W EP 2010060458W WO 2011009849 A2 WO2011009849 A2 WO 2011009849A2
Authority
WO
WIPO (PCT)
Prior art keywords
seq
enzyme
nucleic acid
sequence
formula
Prior art date
Application number
PCT/EP2010/060458
Other languages
English (en)
Other versions
WO2011009849A3 (fr
Inventor
Rainer STÜRMER
Nina Schneider
Matthias Boy
Brigitte Achatz
Ralf Rabus
Johann Heider
Original Assignee
Basf Se
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Se, MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. filed Critical Basf Se
Publication of WO2011009849A2 publication Critical patent/WO2011009849A2/fr
Publication of WO2011009849A3 publication Critical patent/WO2011009849A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/62—Carboxylic acid esters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0008—Oxidoreductases (1.) acting on the aldehyde or oxo group of donors (1.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6436—Fatty acid esters

Definitions

  • the present invention relates to a method for obtaining optically active hydroxy compounds through enantioselective reduction of organic keto compounds and methods for obtaining these hydroxy compounds in the two-phase system using enzymes with dehydrogenase activity.
  • Optically active hydroxy compounds such as, for example, ethyl 2-hydroxy-4- phenylbutyrate
  • ACE angiotensin converting enzyme
  • Many of these inhibitors such as enalapril, ramipril, cilazapril, quinapril and lysinapril, have a common general structural feature which is responsible for improved application properties.
  • the feature common to such inhibitors is the S-enantiomer form of the 2-amino-4-phenylbutyrate with the structural formula (Ia).
  • the S-2-hydroxy-4-phenylbutyric acid of the formula Ib (R enantiomer) is used for preparing isomeric compounds.
  • Obtaining chiral compounds through stereospecific microbiological reduction is known (for an overview cf. Simon et al., Angew. Chemie 97, 541 , 1985).
  • the biocatalysts used are often intact microorganisms, for example fungi (e.g. Mucor, Geotrichum, Saccharomyces, Candida) or bacteria (e.g. Proteus, Pseudomonas). It is also possible to use microbial extracts.
  • Electron donors are, for example, carbohydrates (e.g.
  • reductase e.g. through a substrate-specific dehydrogenase.
  • the reduction equivalents required by the reductase are supplied by a coenzyme, e.g. by pyridine nucleotides such as NADH (nicotinamide adenine dinucleotide) and NADPH (nicotinamide adenine dinucleotide phosphate) or by flavin nucleotides such as FMNH (flavin mononucleotide) and FADH (flavin adenine dinucleotide).
  • the reduced nucleotides for their part are usually formed in a series of enzyme-catalyzed steps with the formation of competing electron acceptors or by electron transfer via natural or synthetic mediators (e.g. ferredoxin, viologens). Also known are final reductases which can absorb electrons directly from the mediators.
  • mediators e.g. ferredoxin, viologens.
  • final reductases which can absorb electrons directly from the mediators.
  • Lacerda et al., Tetrahedron: Asymmetry 17, 2006, pages 1186-1 188 describes a method for the microbial reduction of 2-oxo-4-phenylbutyrates using various bacterial strains.
  • the European patent specification EP 0 347 374 describes a method of preparing R-2- hydroxy-4-phenylbutyric acid in which the substrate is reduced with the enzyme D-lactate dehydrogenase from Staphylococcus epidermidis in the presence of an electron donor and an enzyme-substrate system for regenerating the electron donor.
  • WO2005/049816 discloses a NADPH-dependent dehydrogenase from Metschnikowia zobellii which, in the presence of water and NADPH, catalyzes the stereoselective reduction of carbonyl compounds to the corresponding chiral hydroxy compounds.
  • EP 0 645 453 discloses an enantioselective alcohol dehydrogenase which is suitable for the reduction of organic keto compounds to the corresponding hydroxy compounds, this reduction leading enantioselectively to the corresponding R compounds.
  • the object of the invention was to find a route for the enantioselective reduction of 2-oxo acid esters, in particular ethyl 2-oxo-4-phenylbutyrate, wherein the reaction method should lead as quantitatively as possible to the product by a cost-effective route.
  • the invention firstly provides a method for preparing optically active 2-hydroxy acid ester derivatives of the formula (I),
  • R1 and R2 independently of one another, are
  • alkenyl is straight-chain or branched and comprises one, two, three or four double bonds depending on chain length
  • alkynyl is straight-chain or branched and optionally
  • halogen such as fluorine, chlorine, bromine or iodine
  • alkyl is straight or branched and is unsubstituted or mono- to trisubstituted by halogen, hydroxyl, amino or nitro, or
  • R1 -C(O)-C(O)-O-R2 with an enzyme (E) selected from the class of the dehydrogenases, in the presence of reduction equivalents, wherein the compound of the formula (II) is enzymatically reduced to the compound of the formula (I), and the reduction equivalents consumed in the course of the reaction are regenerated again by converting a reducing agent (RA) to the
  • the -OH group of the formula (I) is in the S configuration (Ia) or in the R configuration (Ib) relative to the carbon atom to which it is bonded.
  • Enzymes (E) suitable according to the invention are in particular the enzymes of the families of the aldo-keto reductases of the aldo-keto reductase superfamily (K.M.Bohren, B. Bullock, B.Wermuth and K.H.Gabbay J.Biol. Chem. 1989, 264, 9547-9551 ) and of the short-chain alcohol dehydrogenases/reductases (SDR).
  • SDR short-chain alcohol dehydrogenases/reductases
  • an enzyme with dehydrogenase activity which can be prepared from microorganisms of the genera Azoarcus (also known to the person skilled in the art under the newer name Aromatoleum), Azonexus, Azospira, Azovibrio, Dechloromonas, Ferribacterium, Petrobacter, Propionivibrio, Quadricoccus, Rhodocyclus, Sterolibacterium, Thauera and Zoogloea.
  • dehydrogenases from species of the genus Azoarcus On account of their amino acid sequence, the phenylethanol dehydrogenase from Azoarcus sp EbN1 can be included in the short-chain alcohol dehydrogenases/reductases (SDR).
  • SDR short-chain alcohol dehydrogenases/reductases
  • the enzyme group is described in detail, for example, in H.J ⁇ rnvall, B.Persson, M.Krook, S.Atrian, R.Gonzalez-Duarte, J.Jeffery and D.Ghosh, Biochemistry, 1995, 34, pp. 6003- 6013 or U.Oppermann, C.Filling, M. HuIt, N.Shafqat, X.Q.Wu, M.Lindh, J.Shafqat,
  • Azoarcus species are Azoarcus anaerobius, Azoarcus buckelii, Azoarcus communis, Azoarcus evansii, Azoarcus indigens, Azoarcus toluclasticus, Azoarcus tolulyticus, Azoarcus toluvorans, Azoarcus sp., Azoarcus sp. 22LJn, Azoarcus sp. BH72, Azoarcus sp. CC-1 1 , Azoarcus sp. CIB, Azoarcus sp. CR23, Azoarcus sp. EB1 , Azoarcus sp. EbN1 , Azoarcus sp.
  • a suitable embodiment of the invention is the use of enzymes (E) in the method specified above, wherein E has a polypeptide sequence (i) SEQ ID NO: 2 or 4 or (ii) has a polypeptide sequence in which up to 25% of the amino acid residues are altered compared with SEQ ID NO:2 or 4 through deletion, insertion, substitution or a combination thereof and which still has at least 50% of the enzymatic activity of SEQ ID NO:2 or 4.
  • the enzyme with dehydrogenase activity is selected from enzymes which comprise an amino acid sequence according to SEQ ID NO:2 or SEQ ID NO:4 or a sequence derived therefrom in which up to 25%, preferably up to 20%, particularly preferably up to 15%, in particular up to 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 %, of the amino acid residues have been altered through a deletion, a substitution, an insertion or a combination of deletion, substitution and insertion, wherein the polypeptide sequences altered compared with SEQ ID NO:2 or SEQ ID NO:4 still have at least 50%, preferably 65%, particularly preferably 80%, in particular more than 90%, of the enzymatic activity of SEQ ID NO:2 or SEQ ID NO:4.
  • the sacrificial alcohol added is used not only to regenerate the consumed reduction equivalents, but also as cosolvent.
  • Preference is given to working in a liquid two-phase system, wherein the one phase consists of water or water- miscible solvent, and the other phase consists of the sacrificial alcohol.
  • Preference is given to using 2-pentanol, 2-butanol or n-heptane as sacrificial alcohol.
  • the reduction equivalents in particular of NADH or NADPH, are preferably used in an amount of from 0.001 to 100 mmol, particularly preferably from 0.01 to 1 mmol, of reduction equivalents per mole of ethyl 2-oxo-4-phenylbutyrate (II) used.
  • the microorganism may in particular be a recombinant microorganism which has been transformed with a nucleic acid construct which codes for an enzyme with dehydrogenase activity in accordance with the above definition.
  • the invention relates to expression cassettes comprising, in operative linkage with at least one regulative nucleic acid sequence, a coding nucleic acid sequence according to the above definition.
  • the invention further provides recombinant vectors comprising at least one such expression cassette.
  • the invention also relates to prokaryotic or eukaryotic hosts which have been transformed with at least one vector according to the invention.
  • the invention further provides the use of an enzyme with dehydrogenase activity according to the above definition or of a microorganism producing this enzyme for preparing compounds of the formulae Ia or Ib.
  • Figure 8 OPB reaction at pH 6.0 and pH 7.0
  • EbN1_para amino acid sequence SEQ ID NO : 3
  • ChnA amino acid sequence
  • Halogen is fluorine, chlorine, bromine or iodine, in particular fluorine or chlorine.
  • “Lower alkyl” is straight-chain or branched alkyl residues having 1 to 6 carbon atoms, such as methyl, ethyl, isopropyl or n-propyl, n-, iso, sec- or tert-butyl, n-pentyl or 2-methylbutyl, n-hexyl, 2-methylpentyl, 3-methylpentyl, 2-ethylbutyl.
  • (C1 -C20)-Alkyl is a hydrocarbon residue whose carbon chain is straight-chain or branched and comprises 1 to 20 carbon atoms, for example methyl, ethyl, propyl, isopropyl, butyl, tertiary-butyl, pentyl, hexyl, heptyl, octyl, nonenyl or decanyl.
  • (C3-C7)-Cycloalkyl is cyclic hydrocarbon residues such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl.
  • “Lower alkenyl” is the mono- or polyunsaturated, preferably mono- or diunsaturated, analogs of the aforementioned alkyl residues having 2 to 6 carbon atoms, wherein the double bond can be in any desired position on the carbon chain.
  • “Lower alkoxy” is the oxygen-terminated analogs of the above alkyl residues.
  • Aryl is aromatic carbon residues having 6 to 14 carbon atoms in the ring.
  • -(C6-C14)-Aryl residues are, for example, phenyl, naphthyl, for example 1 -naphthyl, 2-naphthyl, biphenylyl, for example 2-biphenylyl, 3-biphenylyl and 4-biphenylyl, anthryl or fluorenyl.
  • Biphenylyl residues, naphthyl residues and in particular phenyl residues are preferred aryl residues.
  • (C5-C14)-Heterocycle is a monocyclic or bicyclic 5-membered to 14-membered
  • heterocyclic ring which is partially saturated or completely saturated.
  • heteroatoms are N, O and S.
  • Examples of the terms -(C5-C14)-heterocycle are residues derived from pyrrole, furan, thiophene, imidazole, pyrazole, oxazole, isoxazole, thiazole, isothiazole, tetrazole, 1 ,2,3,5-oxathiadiazole 2-oxides, triazolones, oxadiazolones, isoxazolones, oxadiazolidinediones, triazoles, which are substituted by F, -CN, -CF3 or -C(O)-O-(CI -C4)-alkyl, 3-hydroxypyrro-2,4-diones, 5-oxo-1 ,2,4-thiadiazoles, pyridine, pyrazine, pyrimidine, indole, isoindole,
  • phenylpyrrolyl such as 4- or 5-phenyl-2-pyrrolyl, 2-furyl, 2-thienyl, 4-imidazolyl, methylimidazolyl, for example 1 -methyl-2-, -4- or -5-imidazolyl, 1 ,3-thiazol-2-yl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-, 3- or 4-pyridyl N-oxide, 2-pyrazinyl, 2-, 4- or 5-pyrimidinyl, 2-, 3- or 5-indolyl, substituted 2-indolyl, for example 1 -methyl-, 5-methyl-, 5-methoxy-, 5-benzyloxy-, 5-chloro- or 4,5-dimethyl-2-indolyl, 1 -benzyl-2- or -3-indolyl, 4,5,6,7- tetrahydro-2-ind
  • 2-oxo acid esters of the formula (II) comprise, for example, ethyl 2-oxovalerate, ethyl 2-oxo-4-phenylbutyrate (formula (III)), ethyl pyruvate, ethylphenyl glyoxylate, ethyl-2- oxo-3-phenylpropionic acid, ethyl 8-chloro-6-oxooctanoate, ethyl 2-oxobutyrate, ethyl 2-oxohexanoate, methylphenyl glyoxylate, methyl 2-oxovalerate, methyl pyruvate, methyl 2-oxo-4-phenylbutyrate, methyl-2-oxo-3-phenylpropionic acid, methyl 8-chloro-6- oxooctanoate, methyl 2-oxobutyrate or
  • the S- and R-2-hydroxy acid esters formed correspondingly by reduction comprise, for example, ethyl S- or R-2-hydroxyvalerate, ethyl S-2 or R-hydroxy-4-phenylbutyrate, ethyl L-lactate or ethyl S-mandelate.
  • the invention provides a method of preparing optically active ethyl S-2 or R-hydroxy-4-phenylbutyrate (formulae 1 a and 1 b), the salt of ethyl S-2 or R-hydroxy-4-phenylbutyric acid.
  • This is also known to the person skilled in the art under the name S- or R-2-hydroxy-4-phenylbutyric acid ethyl ester.
  • Formula Ia HPB; S enantiomer
  • enantioselectivity means that the enantiomer excess ee (in %) of one of the two possible enantiomers is at least 50%, preferably at least 80%, in particular at least 90% and specifically at least 95%.
  • dehydrogenases are primarily NAD- or NADP-dependent dehydrogenases (E. C. 1.1.1.x), in particular alcohol dehydrogenases (E. C.1.1.1.1 or E. C.1.1.1.2), which effect the selective reduction of OPB to HPB.
  • the dehydrogenase is preferably obtained from a microorganism, particularly preferably from a bacterium, a fungus, in particular a yeast, in each case listed in strain collections or obtainable from isolates of a natural source, such as soil samples, biomass samples and the like or by de novo gene synthesis.
  • Preferred enzymes with dehydrogenase activity comprise an amino acid sequence according to SEQ ID NO:2 or SEQ ID NO:4, or a functional equivalent thereof.
  • the dehydrogenase can be used in purified or partially purified form or in the form of the original microorganism or of a recombinant host organism which expresses the
  • dehydrogenase Methods for obtaining and purifying dehydrogenases from microorganisms are sufficiently known to a person skilled in the art, e.g. from K. Nakamura & T. Matsuda, "Reduction of Ketones” in K. Drauz and H. Waldmann, Enzyme Catalysis in Organic
  • Suitable bacteria are, for example, those of the orders of the Burkholderiales,
  • Hydrogenophilales Methylophilales, Neisseriales, Nitrosomonadales, Procabacteriales or Rhodocyclales.
  • Rhodocyclaceae Particular preference is given to dehydrogenases from the genera Azoarcus Azonexus, Azospira, Azovibrio, Dechloromonas, Ferribacterium, Petrobacter, Propionivibrio,
  • Quadricoccus Rhodocyclus
  • Sterolibacterium Thauera and Zoogloea.
  • dehydrogenases from species of the genera Azoarcus.
  • dehydrogenases usually take place in the presence of a suitable cofactor (also referred to as cosubstrate).
  • a suitable cofactor also referred to as cosubstrate.
  • NADH and/or NADPH serves as cofactor for the reduction of the ketone.
  • dehydrogenases can be used as cellular systems which inherently comprise cofactors, or alternative redox mediators can be added (A.
  • the reduction with the dehydrogenase usually takes place in the presence of a suitable reducing agent which regenerates the cofactor oxidized in the course of the reduction.
  • suitable reducing agents are sugars, in particular the hexoses, such as glucose, mannose, fructose, and/or oxidizable alcohols, in particular ethanol, propanol, butanol, pentanol or isopropanol, and also formate, phosphite or molecular hydrogen.
  • a second dehydrogenase can be added, such as e.g.
  • glucose dehydrogenase when using glucose as reducing agent phosphite dehydrogenase when using phosphite as reducing agent or formate dehydrogenase when using formate as reducing agent.
  • This can be used as free or immobilized enzyme or in the form of free or immobilized cells. Their preparation can take place either separately or through coexpression in a (recombinant) dehydrogenase strain.
  • the dehydrogenases used according to the invention can be used in free or immobilized form.
  • An immobilized enzyme is understood as meaning an enzyme which is fixed to an inert support. Suitable support materials and the enzymes immobilized thereon are known from EP-A-1 149849, EP-A-1 069 183 and DE-A 100193773 and also from the literature references cited therein. Reference is made to the disclosure of these specifications in its entirety in this regard.
  • Suitable support materials include, for example, clays, clay minerals, such as kaolinite, diatomaceous earth, perlite, silicon dioxide, aluminum oxide, sodium carbonate, calcium carbonate, cellulose powder, anionic exchanger materials, synthetic polymers, such as polystyrene, acrylic resins, phenol formaldehyde resins, polyurethanes and polyolefins, such as polyethylene and polypropylene.
  • the support materials are usually used in a finely divided, particulate form, with porous forms being preferred.
  • the particle size of the support material is usually not more than 5 mm, in particular not more than 2 mm (sieve grade).
  • a free or immobilized form may be chosen.
  • Support materials are, for example, Ca alginate, and carrageenan.
  • Enzymes and also cells can also be crosslinked directly with glutaraldehyde (crosslinking to CLEAs).
  • glutaraldehyde crosslinking to CLEAs.
  • Corresponding and further immobilization methods are described, for example, in J. Lalonde and A. Margolin "Immobilization of Enzymes" in K. Drauz and H. Waldmann, Enzyme Catalysis in Organic Synthesis 2002, Vol. Ill, 991 -1032, Wiley-VCH, Weinheim.
  • “functional equivalents” of the specifically disclosed enzymes with dehydrogenase activity are also included according to the invention.
  • “functional equivalents” or analogs of the specifically disclosed enzymes are polypeptides different therefrom which furthermore have the desired biological activity, such as, for example, substrate specificity.
  • “functional equivalents” are understood as meaning enzymes which reduce from 3-chloro-1 - (thien-2-yl)propan-1 -one to the corresponding S-alcohol and which has at least 50%, preferably 60%, particularly preferably 75%, very particularly preferably 90%, of the activity of an enzyme with the amino acid sequence listed in SEQ ID NO:2 or SEQ ID NO:4.
  • functional equivalents are preferably stable between pH 4 to 10 and
  • “functional equivalents” are in particular also understood as meaning mutants which have a different amino acid to those specifically mentioned in at least one sequence position of the aforementioned amino acid sequences but nevertheless have one of the aforementioned biological activities.
  • “Functional equivalents” thus comprise the mutants obtainable by one or more amino acid additions, substitutions, deletions and/or inversions, it being possible for the said alterations to occur in any sequence position provided they lead to a mutant with the profile of properties according to the invention.
  • Functional equivalence is in particular also present if the reactivity patterns between mutant and unaltered polypeptide are in qualitative agreement, i.e. for example identical substrates are reacted at a different rate.
  • “Functional equivalents” in the above sense are also “precursors” of the described polypeptides and also “functional derivatives” and “salts” of the polypeptides.
  • “precursors” are natural or synthetic precursors of the polypeptides with or without the desired biological activity.
  • salts is understood as meaning both salts of carboxyl groups and also acid addition salts of amino groups of the protein molecules according to the invention.
  • Salts of carboxyl groups can be prepared in a manner known per se and comprise inorganic salts, such as, for example, sodium, calcium, ammonium, iron and zinc salts, and also salts with organic bases, such as, for example, amines, such as triethanolamine, arginine, lysine, piperidine and the like.
  • Acid addition salts such as, for example, salts with mineral acids, such as hydrochloric acid or sulfuric acid, and salts with organic acids, such as acetic acid and oxalic acid, are likewise provided by the invention.
  • “Functional derivatives” of polypeptides according to the invention can likewise be prepared on functional amino acid side groups or on their N- or C-terminal end with the help of known techniques.
  • Derivatives of this type comprise, for example, aliphatic esters of carboxylic acid groups, amides of carboxylic acid groups, obtainable through reaction with ammonia or with a primary or secondary amine; N-acyl derivatives of free amino groups, prepared by reaction with acyl groups; or O-acyl derivatives of free hydroxy groups, prepared by reaction with acyl groups.
  • “Functional derivatives” of polypeptides according to the invention can likewise be prepared on functional amino acid side groups or on their N- or C-terminal end with the help of known techniques.
  • Derivatives of this type comprise, for example, aliphatic esters of carboxylic acid groups, amides of carboxylic acid groups, obtainable through reaction with ammonia or with a primary or secondary amine; N-acyl derivatives of free amino groups, prepared by reaction with acyl groups; or O-acyl derivatives of free hydroxy groups, prepared by reaction with acyl groups.
  • “Functional equivalents” naturally also comprise polypeptides which are accessible from other organisms, and also naturally occurring variants. For example, through sequence comparison, it is possible to establish areas of homologous sequence regions and, in accordance with the specific details of the invention, determine equivalent enzymes.
  • “Functional equivalents” likewise comprise fragments, preferably individual domains or sequence motifs, of the polypeptides according to the invention which, for example, have the desired biological function.
  • “functional equivalents” are fusion proteins which have one of the aforementioned polypeptide sequences or functional equivalents derived therefrom and at least one further, functionally different therefrom, heterologous sequence in functional N- or C-terminal linkage (i.e. without mutual essential functional impairment of the fusion protein parts).
  • Nonlimiting examples of such heterologous sequences are, for example, signal peptides or enzymes.
  • “Functional equivalents” also included according to the invention are homologs to the specifically disclosed proteins. These have at least 60%, preferably at least 75%, in particular at least 85%, such as, for example, 90%, 95% or 99%, homology to one of the specifically disclosed amino acid sequences, calculated according to the algorithm by Pearson and Lipman, Proc. Natl. Acad, Sci. (USA) 85(8), 1988, 2444-2448.
  • a percentage homology of a homologous polypeptide according to the invention means in particular percentage identity of the amino acid residues, based on the total length of one of the amino acid sequences specifically described herein.
  • “functional equivalents” according to the invention comprise proteins of the type referred to above in deglycosylated or glycosylated form and also modified forms obtainable by altering the glycosylation pattern.
  • Homologs of the proteins or polypeptides according to the invention can be produced by mutagenesis, e.g. by point mutation or shortening of the protein.
  • Homologs of the proteins according to the invention can be identified by screening combinatorial libraries of mutants, such as, for example, truncation mutants.
  • a variegated library of protein variants can be produced by combinatorial mutagenesis at the nucleic acid level, such as, for example, by enzymatic ligation of a mixture of synthetic oligonucleotides.
  • the chemical synthesis of a degenerated gene sequence can be carried out in an automated DNA synthesizer, and the synthetic gene can then be ligated into a suitable expression vector.
  • Using a degenerate gene set makes it possible to provide all sequences in a mixture which code for the desired set of potential protein sequences.
  • oligonucleotides are known to the person skilled in the art (e.g. Narang, S. A.
  • REM Recursive ensemble mutagenesis
  • the invention provides in particular nucleic acid sequences (single- and double-stranded DNA and RNA sequences, such as, for example, cDNA and mRNA) which code for an enzyme with dehydrogenase activity according to the invention. Preference is given to nucleic acid sequences which code, for example, for amino acid sequences according to SEQ ID NO:2 or SEQ ID NO:4 or characteristic part sequences thereof, or comprise nucleic acid sequences according to SEQ ID NO:1 or SEQ ID NO:3 or characteristic part sequences thereof, or the complementary strand thereof (a)).
  • nucleic acids comprising a sequence which hybridizes with the DNA sequence according to SEQ ID NO:1 or its complementary strand, wherein the hybridization takes place under stringent conditions (b)), or a DNA sequence which, due to the degeneracy of the genetic code, encodes a protein which is also encoded by a DNA sequence according to a) or b).
  • nucleic acid sequences mentioned herein can be prepared in a manner known per se through chemical synthesis from the nucleotide building blocks, such as, for example, through fragment condensation of individual overlapping, complementary nucleic acid building blocks of the double helix.
  • the chemical synthesis of oligonucleotides can take place, for example, in a known manner in accordance with the phosphoamidite method (Voet, Voet, 2 nd Edition, Wiley Press New York, pages 896-897).
  • the addition of synthetic oligonucleotides and filling of gaps with the help of the Klenow fragment of the DNA polymerase and ligation reactions and also general cloning methods are described in Sambrook et al. (1989), Molecular Cloning: A laboratory manual, Cold Spring Harbor Laboratory Press.
  • the invention also provides nucleic acid sequences (single- and double-stranded DNA and RNA sequences, such as, for example, cDNA and mRNA), coding for one of the above polypeptides and their functional equivalents, which are accessible, for example, using artificial nucleotide analogs.
  • the invention relates both to isolated nucleic acid molecules which code for polypeptides and proteins according to the invention or biologically active sections thereof, and also nucleic acid fragments which can be used, for example, for use as hybridization probes or primers for the identification or amplification of coding nucleic acids according to the invention.
  • nucleic acid molecules according to the invention can comprise untranslated sequences of the 3' and/or 5' end of the coding gene region.
  • the invention comprises the nucleic acid molecules complementary to the specifically described nucleotide sequences, or a section thereof.
  • nucleotide sequences according to the invention allow the production of probes and primers which can be used for the identification and/or cloning of homologous sequences in other cell types and organisms.
  • probes and primers usually comprise a nucleotide sequence region which under "stringent” conditions (see below) hybridizes onto at least about 12, preferably at least about 25, such as, for example, about 40, 50 or 75, consecutive nucleotides of a sense strand of a nucleic acid sequence according to the invention or of a corresponding antisense strand.
  • nucleic acid molecule is separated from other nucleic acid molecules which are present in the natural source of the nucleic acid and can, moreover, be essentially free from other cellular material or culture medium if it is prepared by recombinant techniques, or be free from chemical precursors or other chemicals if it is chemically synthesized.
  • a nucleic acid molecule according to the invention can be isolated by means of molecular biological standard techniques and the sequence information provided according to the invention.
  • cDNA can be isolated from a suitable cDNA library by using one of the specifically disclosed complete sequences or a section thereof as hybridization probe and standard hybridization techniques (as described, for example, in Sambrook, J., Fritsch, E. F. and Maniatis, T. Molecular Cloning: A Laboratory Manual. 2 nd Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989).
  • nucleic acid molecule comprising one of the disclosed sequences or a section thereof can be isolated by polymerase chain reaction, in which case the oligonucleotide primers which have been created on the basis of this sequence are used.
  • the nucleic acid amplified in this way can be cloned into a suitable vector and be characterized by DNA sequence analysis.
  • the oligonucleotides according to the invention can also be prepared by standard synthesis methods, e.g. using an automated DNA synthesis instrument.
  • nucleic acid sequences according to the invention can in principle be identified and isolated from all organisms.
  • the nucleic acid sequences according to the invention or the homologs thereof can be advantageously isolated from fungi, yeasts, archaea or bacteria.
  • Bacteria which may be mentioned are Gram-negative and Gram-positive bacteria.
  • nucleic acids according to the invention from Gram-negative bacteria advantageously from [alpha]-proteobacteria, [beta]-proteobacteria or [gamma]- proteobacteria, particularly preferably from bacteria of the orders of the Burkholderiales, Hydrogenophilales, Methylophilales, Neisseriales, Nitrosomonadales, Procabacteriales or Rhodocyclales. Very particularly preferably from bacteria of the family of Rhodocyclaceae. Particularly preferably from the genus Azoarcus (Aromatoleum).
  • Azoarcus anaerobius Especially preferably from species Azoarcus anaerobius, Azoarcus buckelii, Azoarcus communis, Azoarcus evansii, Azoarcus indigens, Azoarcus toluclasticus, Azoarcus tolulyticus, Azoarcus toluvorans, Azoarcus sp., Azoarcus sp. 22LJn, Azoarcus sp. BH72, Azoarcus sp. CC-1 1 , Azoarcus sp. CIB, Azoarcus sp. CR23, Azoarcus sp. EB1 , Azoarcus sp. EbN1 , Azoarcus sp.
  • Nucleic acid sequences according to the invention can be isolated, for example, using customary hybridization methods or the PCR technique from other organisms, e.g. via genomic or cDNA libraries. These DNA sequences hybridize under standard conditions with the sequences according to the invention. For the hybridization, short oligonucleotides of the preserved regions, for example from the active center, which can be ascertained by means of comparisons with a dehydrogenase according to the invention in the manner known to the person skilled in the art, are advantageously used. However, it is also possible to use longer fragments of the nucleic acids according to the invention or the complete sequences for the hybridization. Depending on the nucleic acid used (oligonucleotide, relatively long fragment or complete sequence) or depending on which nucleic acid type DNA or RNA are used for the hybridization, these standard conditions vary. Thus, for example, the melting
  • temperatures for DNA:DNA hybrids are ca. 1O 0 C lower than those of DNA:RNA hybrids of identical length.
  • the hybridization conditions for DNA:DNA hybrids are advantageously 0.1 * SSC and temperatures between about 2O 0 C to 45 0 C, preferably between about 3O 0 C to 45 0 C.
  • the hybridization conditions are advantageously 0.1 * SSC and temperatures between about 3O 0 C to 55 0 C, preferably between about 45 0 C to 55 0 C.
  • the invention also provides derivatives of the specifically disclosed or derivable nucleic acid sequences.
  • nucleic acid sequences according to the invention can be derived from SEQ ID NO:1 or NO:3 and can differ therefrom through addition, substitution, insertion or deletion of one or more nucleotides, but still code for polypeptides with the desired profile of properties.
  • nucleic acid sequences which comprise so-called silent mutations or have been altered corresponding to the codon usage of a specific source organism or host organism, compared to a specifically specified sequence, as well as naturally occurring variants, such as, for example, splice variants or allele variants.
  • sequences obtainable by conservative nucleotide substitutions i.e. the amino acid in question is replaced by an amino acid of identical charge, size, polarity and/or solubility.
  • nucleic acid sequence derivatives of a nucleic acid sequence according to the invention are to be understood as meaning, for example, allele variants which have at least 40% homology at the derived amino acid level, preferably at least 60% homology, very particularly preferably at least 80, 85, 90, 93, 95 or 98% homology over the entire sequence range (with regard to homology at the amino acid level, reference may be made to the above statements relating to the polypeptides).
  • the homologies may advantageously be higher over part ranges of the sequences.
  • derivatives are also to be understood as meaning homologs of the nucleic acid sequences according to the invention, for example fungal or bacterial homologs, shortened sequences, single-strand DNA or RNA of the coding and noncoding DNA sequence. They had e.g. at the DNA level a homology of at least 40%, preferably of at least 60%, particularly preferably of at least 70%, very particularly preferably of at least 80%, over the entire stated DNA region.
  • derivatives are to be understood as meaning, for example, fusions with promoters.
  • the promoters which are located upstream of the stated nucleotide sequences may have been altered by one or more nucleotide exchanges, insertions, inversions and/or deletions without, however, impairing the functionality and/or effectiveness of the promoters. Furthermore, the promoters can be increased in their effectiveness by altering their sequence or exchanged completely for more effective promoters, including those of organisms of other species.
  • Derivatives are also to be understood as meaning variants whose nucleotide sequence has been altered in the range from -1 to -1000 bases upstream of the start codon or 0 to 1000 bases downstream after the stop codon such that the gene expression and/or the protein expression is altered, preferably increased.
  • the invention also comprises nucleic acid sequences which hybridize with coding sequences specified above under "stringent conditions". These polynucleotides can be found upon screening genomic or cDNA libraries and, if appropriate, can be replicated therefrom using suitable primers by means of PCR and then be isolated, for example using suitable probes. Moreover, polynucleotides according to the invention can also be synthesized by a chemical route. This property is understood as meaning the ability of a poly- or oligonucleotide to bind under stringent conditions to a virtually complementary sequence whereas nonspecific bonds between noncomplementary partners do not take place under these conditions. For this, the sequences should be 70-100%, preferably 90- 100%, complementary.
  • complementary sequences to be able to bond specifically to one another is utilized, for example, in the Northern- or Southern-Blot technique or during primer bonding in PCR or RT-PCR. Usually, for this, oligonucleotides above a length of 30 base pairs are used. Under stringent conditions is understood, for example in the Northern-Blot technique, as meaning the use of a 50-70 0 C, preferably 60- 65 0 C warm washing solution, for example 0. Ix SSC buffer with 0.1 % SDS (2Ox SSC: 3M NaCI, 0.3M Na citrate, pH 7.0) for the elution of nonspecifically hybridized cDNA probes or oligonucleotides.
  • the invention provides expression constructs comprising, under the genetic control of regulative nucleic acid sequences, a nucleic acid sequence coding for a polypeptide according to the invention; and also vectors comprising at least one of these expression constructs.
  • such constructs according to the invention comprise 5'-upstream of the respective coding sequence, a promoter and 3'-d own stream a terminator sequence, and, if appropriate, further customary regulative elements, in each case operatively linked to the coding sequence.
  • An "operative linkage" is understood as meaning the sequential arrangement of promoter, coding sequence, terminator and, if appropriate, further regulative elements such that each of the regulative elements can properly perform its function in expressing the coding sequence.
  • operatively linkable sequences are targeting sequences and also enhancers, polyadenylation signals and the like.
  • Further regulative elements comprise selectable markers, amplification signals, replication origins and the like. Suitable regulatory sequences are described, for example, in Goeddel, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, CA (1990).
  • a nucleic acid construct according to the invention is in particular to be understood as meaning one in which the gene for a dehydrogenase according to the invention have been operatively or functionally linked to one or more regulation signals for controlling, e.g.
  • the natural regulation of these sequences may still be present upstream of the actual structural genes and, if appropriate, may have been genetically altered, such that the natural regulation has been switched off and the expression of the genes has been increased.
  • the nucleic acid construct can also be simpler in design, i.e. no additional regulation signals have been inserted before the coding sequence and the natural promoter with its regulation has not been removed.
  • the natural regulatory sequence is mutated such that regulation no longer takes place and gene expression is increased.
  • a preferred nucleic acid construct advantageously also comprises one or more of the already mentioned “enhancer” sequences, functionally linked to the promoter, which permit increased expression of the nucleic acid sequence. It is also possible to insert additional advantageous sequences at the 3' end of the DNA sequences, such as further regulatory elements or terminators.
  • the nucleic acids according to the invention may be present in one or more copies in the construct. In the construct it is also possible for further markers to be present, such as antibiotic resistances or auxotrophy complementing genes, if appropriate for selection on the construct.
  • Advantageous regulatory sequences for the method according to the invention are present, for example, in promoters such as cos, tac, trp, tet, trp-tet, Ipp, lac, Ipp-lac, lacl ⁇ q->, T7-T5, T3, gal, trc, ara, rhaP (rhaPBAD)SP ⁇ , lambda-PR or in the lambda-PL promoter, which are used advantageously in Gram-negative bacteria.
  • Further advantageous regulatory sequences are present, for example, in the Gram-positive promoters amy and SPO2, in the yeast or fungus promoters ADC 1 , MFalpha, AC, P-60, CYC1 , GAPDH, TEF, rp28, ADH.
  • the promoters of the pyruvate decarboxylase and of the methanol oxidase are also advantageous. It is also possible to use artificial promoters for the regulation.
  • the nucleic acid construct is advantageously inserted into a vector, such as, for example, a plasmid or a phage, which permits optimal expression of the genes in the host.
  • vectors are also to be understood as meaning all other vectors known to the person skilled in the art, thus e.g.
  • viruses such as SV40, CMV, baculovirus and adenovirus, transposons, IS elements, phasmids, cosmids, and linear or cicular DNA.
  • SV40 SV40
  • CMV CMV
  • baculovirus and adenovirus baculovirus
  • transposons IS elements
  • phasmids cosmids
  • linear or cicular DNA a virus that can be replicated autonomously in the host organism or be chromosomally replicated.
  • Suitable plasmids are, for example, in E.
  • the specified plasmids are a small selection of the possible plasmids. Further plasmids are well known to the person skilled in the art and can be found, for example, in the book Cloning Vectors (Eds. Pouwels P. H. et al. Elsevier, Amsterdam-New York-Oxford, 1985, ISBN 0 444 904018).
  • the nucleic acid construct advantageously additionally also comprises 3'- and/or 5'-terminal regulatory sequences for increasing expression, which are selected for optimal expression depending on the selected host organism and gene or genes.
  • regulatory sequences are intended to permit the targeted expression of the genes and of the protein expression. Depending on the host organism, this may mean, for example, that the gene is expressed or overexpressed only after induction, or that it is immediately expressed and/or overexpressed.
  • the regulatory sequences and/or factors can here preferably have a positive influence, and thereby increase, the gene expression of the introduced genes.
  • an enhancement of the regulatory elements can advantageously take place at the transcription level by using strong transcription signals such as promoters and/or "enhancers".
  • an enhancement of the translation is also possible by, for example, improving the stability mRNA.
  • the vector comprising the nucleic acid construct according to the invention or the nucleic acid according to the invention can also
  • This linear DNA can consist of a linearized vector such as a plasmid or only of the nucleic acid construct or the nucleic acid according to the invention.
  • an expression cassette according to the invention takes place through fusion of a suitable promoter with a suitable coding nucleotide sequence and also a terminator or polyadenylation signal.
  • a suitable promoter with a suitable coding nucleotide sequence and also a terminator or polyadenylation signal.
  • customary recombination and cloning techniques are used, as are described, for example, in T. Maniatis, E. F. Fritsch and J.
  • the recombinant nucleic acid construct or gene construct is advantageously inserted into a host-specific vector which allows optimal expression of the genes in the host.
  • Vectors are well known to the person skilled in the art and can be found, for example, in "Cloning Vectors" (Pouwels P. H. et al., Ed., Elsevier, Amsterdam-New York-Oxford, 1985).
  • E. Host organisms which can be used according to the invention With the help of the vectors or constructs according to the invention, it is possible to prepare recombinant microorganisms which are transformed, for example, with at least one vector according to the invention and can be used for the production of the polypeptides according to the invention.
  • the above-described recombinant constructs according to the invention are advantageously introduced into a suitable host system and expressed.
  • customary cloning and transfection methods such as, for example, coprecipitation, protoplast fusion, electroporation, retroviral transfection and the like, known to the person skilled in the art are preferably used in order to express said nucleic acids in the particular expression system.
  • a vector is prepared which comprises at least one section of a gene according to the invention or of a coding sequence in which, if appropriate, at least one amino acid deletion, addition or substitution has been inserted in order to alter the sequence according to the invention, e.g. to functionally disrupt it ("knockout" vector).
  • the introduced sequence can, for example, also be a homolog from a related microorganism or derived from a mammal, yeast or insect source.
  • the vector used for the homologous recombination can alternatively be configured such that the endogenous gene is mutated or altered in some other way during homologous recombination, but still codes for the functional protein (e.g. the regulatory region positioned upstream can be altered in such a way that the expression of the endogenous protein is thereby altered).
  • the altered section of the gene according to the invention is in the homologous recombination vector.
  • suitable vectors for the homologous recombination is described, for example, in Thomas, K.R. and Capecchi, M. R. (1987) Cell 51 :503.
  • Suitable recombinant host organisms for the nucleic acid according to the invention or the nucleic acid construct are in principle all prokaryotic or eukaryotic organisms.
  • the host organisms used are advantageously microorganisms such as bacteria, fungi or yeasts.
  • Gram-positive or Gram-negative bacteria are advantageously used, preferably bacteria of the families Enterobacteriaceae, Pseudomonadaceae, Rhizobiaceae, Streptomycetaceae or Nocardiaceae, particularly preferably bacteria of the genera Escherichia, Pseudomonas, Streptomyces, Nocardia, Burkholderia, Salmonella, Agrobacterium or Rhodococcus.
  • the genus and species is Escherichia coli.
  • advantageous bacteria can be found in the group of alpha-proteobacteria, beta- proteobacteria or gamma-proteobacteria.
  • the host organism or the host organisms according to the invention comprise here preferably at least one of the nucleic acid sequences described in this invention, nucleic acid constructs or vectors which code for an enzyme with dehydrogenase activity according to the invention.
  • the organisms used in the method according to the invention can be grown or cultivated depending on the host organism in the manner known to the person skilled in the art.
  • Microorganisms are usually grown in a liquid medium which comprises a carbon source mostly in the form of sugars, a nitrogen source mostly in the form of organic nitrogen sources such as yeast extract or salts such as ammonium sulfate, trace elements such as iron, manganese, magnesium salts and, if appropriate, vitamins, at temperatures between O 0 C and 100 0 C, preferably between 1 O 0 C to 6O 0 C with oxygen gassing.
  • the pH of the nutrient liquid can be kept at a fixed value, i.e. may or may not be regulated during cultivation.
  • the cultivation can take place batchwise, semibatchwise or continuously.
  • Nutrients can be initially introduced at the start of the fermentation or be fed in afterwards semicontinuously or continuously.
  • the ketone can be added directly for the cultivation or advantageously after cultivation.
  • the enzymes can be isolated from the organisms by the method described in the examples or be used as crude extract for the reaction.
  • the invention further provides methods for the recombinant preparation of polypeptides according to the invention or functional, biologically active fragments thereof, wherein a polypeptide-producing microorganism is cultivated, if appropriate the expression of the polypeptides is induced and these are isolated from the culture.
  • the polypeptides can thus also be produced on an industrial scale, if desired.
  • the recombinant microorganism can be cultivated and fermented by known methods.
  • Bacteria can be replicated, for example, in TB or LB medium and at a temperature of from 20 to 4O 0 C and a pH of from 6 to 9. Suitable cultivation conditions are described in detail, for example, in T. Maniatis, E. F. Fritsch and J. Sambrook, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1989).
  • the cells are disrupted and the product obtained from the lysate by known protein isolation methods.
  • the cells can be disrupted by high-frequency ultrasound, by high pressure, such as, for example, in a French pressure cell, by osmolysis, through the effect of detergents, lytic enzymes or organic solvents, by homogenizers or by combining two or more of the listed methods.
  • Purification of the polypeptides can be achieved using known chromatographic methods, such as molecular sieve chromatography (gel filtration), such as Q-sepharose
  • vector systems or oligonucleotides which extend the cDNA by certain nucleotide sequences and thus code for altered polypeptides or fusion proteins which serve, for example, for simpler purification.
  • Suitable modifications of this type are, for example, so-called “tags” functioning as anchors, such as, for example, the modification known as hexa-histidine anchor, or epitopes which can be recognized as antigens of antibodies (described, for example, in Harlow, E. and Lane, D., 1988, Antibodies: A Laboratory Manual. Cold Spring Harbor (N. Y.) Press).
  • anchors can serve for attaching the proteins to a solid support, such as, for example, a polymer matrix, which can be poured, for example, into a chromatography column, or can be used on a microtiter plate or some other support.
  • these anchors can also be used for recognizing the proteins.
  • customary markers such as fluorescent dyes, enzyme markers which form a detectable reaction product following reaction with a substrate, or radioactive markers, alone or in combination with the anchors for derivatization of the proteins.
  • the reaction can take place in aqueous or nonaqueous reaction media or in two-phase systems or (micro)emulsions.
  • the aqueous reaction media are preferably buffered solutions which generally have a pH between pH 4 and 12, preferably between 4.5 to 9, particularly preferably between 5 to 8.
  • the aqueous solvent can moreover comprise at least one alcohol, e.g. ethanol or isopropanol or dimethyl sulfoxide.
  • Nonaqueous reaction media are understood as meaning reaction media which comprise less than 1 % by weight, preferably less than 0.5% by weight, of water, based on the total weight of the reaction medium.
  • the reaction is preferably carried out in an organic solvent.
  • Suitable solvents are, for example, aliphatic hydrocarbons, preferably having 5 to 8 carbon atoms, such as pentane, cyclopentane, hexane, cyclohexane, heptane, octane or cyclooctane, halogenated aliphatic hydrocarbons, preferably having one or two carbon atoms, such as dichloromethane, chloroform, tetrachloromethane, dichloroethane or tetrachloroethane, aromatic hydrocarbons, such as benzene, toluene, the xylenes, chlorobenzene or dichlorobenzene, aliphatic acyclic and cyclic ether
  • the reduction with the dehydrogenase is carried out in an aqueous-organic, in particular aqueous, reaction medium.
  • the ketone to be reduced is preferably used in the enzymatic reduction in a concentration of from 0.1 g/l to 500 g/l, particularly preferably from 1 g/l to 100 g/l and can be conveyed continuously or discontinuously.
  • the enzymatic reduction usually takes place at a reaction temperature below the
  • deactivation temperature of the dehydrogenase used is preferably at least -1 O 0 C. It is particularly preferably in the range from 0 to 100 0 C, in particular from 5 to 6O 0 C and specifically from 10 to 4O 0 C, and very particularly preferably between 30° and 4O 0 C.
  • the ketone can, for example, be initially introduced with the
  • dehydrogenase, the solvent and, if appropriate, the coenzymes, if appropriate a second dehydrogenase for regenerating the coenzyme and/or further reducing agents and the mixture can be thoroughly mixed, e.g. by stirring or shaking.
  • immobilize the dehydrogenase(s) in a reactor for example in a column, and to feed through the reactor a mixture comprising the ketone and, if appropriate, coenzymes and/or cosubstrates.
  • the mixture can be circulated through the reactor until the desired conversion is reached.
  • the keto group of the ketone is reduced to an OH group with essentially one of the two enantiomers of the alcohol being formed.
  • the reduction will be carried out up to a conversion of at least 70%, particularly preferably of at least 85% and in particular of at least 95%, based on the ketone present in the mixture.
  • the progress of the reaction i.e. the sequential reduction of the ketone, can be monitored here by customary methods such as gas chromatography or high-pressure liquid
  • enantiomerically pure or chiral products or optically active alcohols are to be understood as meaning enantiomers which exhibit an enantiomer enrichment.
  • enantiomer purities of at least 70% ee, preferably of at least 80% ee, particularly preferably of at least 90% ee, very particularly preferably at least 98% ee are achieved.
  • the inventors have, moreover, recognized that the enantiomer unit in particular of the R enantiomer (formula Ib) can be considerably increased if, at the end of the dehydrogenase reaction, a lipase is added to the mixture which saponifies the undesired S enantiomer to the free acid, which can be separated off in the subsequent work-up in accordance with methods known to the person skilled in the art [J. Org. Chem. 1990, 55, 812-815].
  • Saponification is generally understood as meaning the basic hydrolysis of esters into their constituents alcohol and acid. The reaction is irreversible.
  • enzymes of the class of the hydrolases (EC 3), specifically of the esterases (EC 3.1 ), particularly preferably of the class (EC 3.1.1.3: triacylglycerol acyl hydrolases), which specifically cleave fats
  • triglycerides into glycerol and fatty acids.
  • the person skilled in the art is familiar with a series of lipase from fungi (Aspergillis, Candida, Geotrichum, Humicola, Mucor, Rhizopus) and from bacteria (Chromobacterium, Pseudomonas), which are suitable for the method according to the invention.
  • fungi Aspergillis, Candida, Geotrichum, Humicola, Mucor, Rhizopus
  • bacteria Chromobacterium, Pseudomonas
  • Disrupted cells are to be understood as meaning, for example, cells which have been rendered permeable via a treatment with, for example, solvents, or cells which have been broken open via an enzyme treatment, via a mechanical treatment (e.g. French press or ultrasound) or via some other method.
  • the crude extracts obtained in this way are advantageously suitable for the method according to the invention.
  • Purified or partly purified enzymes can also be used for the method.
  • immobilized microorganisms or enzymes which can be used advantageously in the reaction.
  • HPB ethyl S-2-hydroxy-4-phenylbutyrate
  • HPB ethyl S-2-hydroxy-4-phenylbutyrate
  • the extraction can be repeated several times to increase the yield.
  • suitable extractants are solvents, such as toluene, methylene chloride, butyl acetate, diisopropyl ether, benzene, MTBE or acetic ester, without being limited thereto. Particular preference is given to MTBE as extractant.
  • the product (HPB) prepared in the method according to the invention can advantageously be obtained from the organic phase of the reaction solution by means of extraction or distillation and/or crystallization.
  • the extraction can be repeated several times to increase the yield.
  • suitable extractants are solvents, such as toluene, methylene chloride, butyl acetate, diisopropyl ether, benzene, MTBE or acetic ester, without being limited thereto.
  • the products can generally be obtained in good chemical purities, i.e. greater than 80% chemical purity.
  • the organic phase containing the product can, however, also only be partly evaporated and the product crystallized out.
  • the solution is advantageously cooled to a temperature of from O 0 C to 1 O 0 C.
  • the crystallization can also take place directly from the organic solution or from an aqueous solution.
  • the crystallized-out product can be taken up again in the same solvent or in a different solvent for recrystallization and be crystallized again.
  • the enantiomer purity of the product can be further increased if required.
  • the product of the method according to the invention can be isolated in yields of from 60 to 100%, preferably from 80 to 100%, particularly preferably from 90 to 100%, based on the substrate OPB used for the reaction.
  • the isolated product is characterized by a high chemical purity of > 90%, preferably > 95%, particularly preferably of > 98%.
  • the products have a high enantiomer purity, which can advantageously, if required, be further increased through the crystallization.
  • the method according to the invention can be operated batchwise, semibatchwise or continuously.
  • the advantage of the method according to the invention is the particularly high yield of the optically active HPB of the formula (Ia, Ib) or of the virtually quantitative conversion of OPB (II).
  • the invention will be illustrated in more detail by reference to the examples below, without limiting the invention thereto.
  • the EbN1_para (LU13150) here was identified as a suitable biocatalyst for preparing the S enantiomer (1 a). This dehydrogenase completely converts the ketone with ee > 95%.
  • the enzyme is the paralogous protein to EbN1 , which originates from an Azoarcus library.
  • ChnA (LU13283) has been identified as the only R-selective enzyme and likewise originates from the aforementioned Azoarcus library. To guarantee the findings, a second screening was carried out with a further series of dehydrogenases.
  • Fig. 2 shows both the ee values from the GC and also from the chiral HPLC. It can be seen that ChnA produces the highest ee values for the R enantiomer.
  • the SDR enzymes short chain dehydrogenases which, like the ChnA, also originate from the Azoarcus library exhibit very poor enantioselectivities apart from SDR2.
  • the Re-ADH from Rhodococcus IEP
  • the symbol ">" means that the actual activities are greater since the substrate was already completely converted.
  • Example 2 Preparation of ethyl S-2-hydroxy-4-phenylbutyrate (1 a)
  • Figure 3 shows that by using a solvent the conversion proceeds significantly more rapidly than in the single-phase mixture.
  • One reason for this may be the higher solubility of the substrate in 2-butanol.
  • ChnA (LU13283) originates from the Azoarcus library from which EbN1 , biocatalyst in the preparation of duloxetine alcohol, also originates.
  • the sequence of the nucleic acid coding for the ChnA has the SEQ ID NO: 1.
  • Fig. 6 shows that somewhat better ee values are achieved at lower temperatures.
  • 2-butanol was tested since 2-butanol is considerably less expensive. 5 g/l (bio dry mass) of cells and 150 mM (75 mmol, 15.5 g) of ethyl 2-oxo-4-phenylbutyrate (1 ) were initially introduced in 250 ml of buffer (50 mM
  • FIG. 18 (a)-(c) shows a comparison of different lipases and lipase batches (a) squares: Pseudomonas Lipase, as described in WO 95/08636, used at a cone, of 0,125 g/L at 5O 0 C ; triangles: amano lipase as used above). Amano Lipase was used at a cone, of 2,5 g/L.
  • the amano lipase was added in portions (see fig. 17) without inactivating the dehydrogenase beforehand.
  • the dehydrogenase does not disturb the saponification.
  • a lipase step has to be added in order to achieve an ee value of more than 99%.
  • Amano lipase from Pseudomonas selectively saponifies the S enantiomer to give the acid, moreover it is very cost-effective and available in large amounts.
  • the saponification is relatively slow in the two-phase system, meaning that an ee > 99% with 1 g/l of amano lipase is only achieved after 4 days.
  • This step can be optimized by means of methods known to the person skilled in the art, e.g. amount of lipase or solvent used. Further lipases can be tested and compared. The experiments show that the initial ee value (81 %) can be increased to more than 95% by optimizing the conditions.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention porte sur un procédé pour la préparation de dérivés esters de 2-hydroxyacides optiquement actifs représentés par la formule R1-C(OH)-C(O)-O-R2 (I), comprenant la mise en contact de dérivés esters de 2-oxoacides représentés par la formule R1-C(O)-C(O)-O-R2 (II) avec une enzyme (E) choisie dans la classe des déshydrogénases, en présence d'équivalents de réduction, le composé représenté par la formule (II) étant réduit par voie enzymatique en le composé représenté par la formule (I) et les équivalents de réduction consommés au cours de la réaction étant régénérés à nouveau par conversion d'un agent réducteur (RA) en le produit d'oxydation correspondant (OP) à l'aide de l'enzyme (E). L'invention porte en outre sur une déshydrogénase qui réduit des esters de 2-oxoacides en présence d'équivalents de réduction en les esters de S-2-hydroxyacides et également sur un acide nucléique codant pour la déshydrogénase.
PCT/EP2010/060458 2009-07-21 2010-07-20 Procédé pour la préparation d'esters d'hydroxyacides optiquement actifs WO2011009849A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP09166015.9 2009-07-21
EP09166015 2009-07-21
US22779709P 2009-07-23 2009-07-23
US61/227,797 2009-07-23

Publications (2)

Publication Number Publication Date
WO2011009849A2 true WO2011009849A2 (fr) 2011-01-27
WO2011009849A3 WO2011009849A3 (fr) 2011-04-07

Family

ID=43499462

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/060458 WO2011009849A2 (fr) 2009-07-21 2010-07-20 Procédé pour la préparation d'esters d'hydroxyacides optiquement actifs

Country Status (2)

Country Link
TW (1) TW201109441A (fr)
WO (1) WO2011009849A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9758500B2 (en) 2012-04-16 2017-09-12 Basf Se Process for the preparation of (3E, 7E)-homofarnesol
CN110555138A (zh) * 2019-08-05 2019-12-10 慧镕电子系统工程股份有限公司 一种云计算架构下的混合云存储方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0347374A1 (fr) 1988-06-06 1989-12-20 Ciba-Geigy Ag Procédé de préparation d'acides hydroxylés
EP0645453A2 (fr) 1993-09-24 1995-03-29 Daicel Chemical Industries, Ltd. Déhydrogénase d'alcool, DNA, codant pour celle-ci, préparation et méthode de préparation d'alcools optiquement actifs
WO1995008636A1 (fr) 1993-09-25 1995-03-30 Basf Aktiengesellschaft Clivage de racemates d'amines primaires et secondaires par acylation catalysee par enzyme
EP1069183A2 (fr) 1999-07-09 2001-01-17 Basf Aktiengesellschaft Lipase immobilisée
EP1093773A1 (fr) 1999-10-21 2001-04-25 Karl Storz GmbH & Co. KG Corps de fixation biodégradable
EP1149849A1 (fr) 2000-04-19 2001-10-31 Basf Aktiengesellschaft Procédé pour la préparation de materieux bioactifs liées de maniere covalente à des mousses de polyuréthanne rt l'utilisation de supports de mousses polyuréthanne pour les sythèses chirales
WO2005049816A2 (fr) 2003-11-21 2005-06-02 Juelich Enzyme Products Gmbh Oxydoreductase de metschnikowia zobellii

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2691799C (fr) * 2007-06-20 2016-06-07 Basf Se Procede de production d'alcools optiquement actifs a l'aide d'une deshydrogenase tiree de azoarcus sp. ebn1

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0347374A1 (fr) 1988-06-06 1989-12-20 Ciba-Geigy Ag Procédé de préparation d'acides hydroxylés
EP0645453A2 (fr) 1993-09-24 1995-03-29 Daicel Chemical Industries, Ltd. Déhydrogénase d'alcool, DNA, codant pour celle-ci, préparation et méthode de préparation d'alcools optiquement actifs
WO1995008636A1 (fr) 1993-09-25 1995-03-30 Basf Aktiengesellschaft Clivage de racemates d'amines primaires et secondaires par acylation catalysee par enzyme
EP1069183A2 (fr) 1999-07-09 2001-01-17 Basf Aktiengesellschaft Lipase immobilisée
EP1093773A1 (fr) 1999-10-21 2001-04-25 Karl Storz GmbH & Co. KG Corps de fixation biodégradable
EP1149849A1 (fr) 2000-04-19 2001-10-31 Basf Aktiengesellschaft Procédé pour la préparation de materieux bioactifs liées de maniere covalente à des mousses de polyuréthanne rt l'utilisation de supports de mousses polyuréthanne pour les sythèses chirales
WO2005049816A2 (fr) 2003-11-21 2005-06-02 Juelich Enzyme Products Gmbh Oxydoreductase de metschnikowia zobellii

Non-Patent Citations (19)

* Cited by examiner, † Cited by third party
Title
ARKIN; YOURVAN PNAS vol. 89, 1992, pages 7811 - 7815
BLASER, H.-U.; BURKHARDT, S.; KIMER, HANS J.; MOESSNER, T.; STUDER, M. SYNTHESIS vol. 11, 2003, pages 1679 - 1682
C.FILLING; K.D.BERNDT; J.BENACH; S.KNAPP; T.PROZOROVSKI; E.NORDLING; R.LADENSTEIN; H.JORNVALL; U.OPPERMANN JOURNAL OF BIOLOGICAL CHEMISTRY vol. 277, 2002, pages 25677 - 25684
DELGRAVE ET AL. PROTEIN ENGINEERING vol. 6, no. 3, 1993, pages 327 - 331
H.J6RNVALL; B.PERSSON; M.KROOK; S.ATRIAN; R.GONZAEZ-DUARTE; J.JEFFERY; D.GHOSH BIOCHEMISTRY vol. 34, 1995, pages 6003 - 6013
H.J6RNVALL; B.PERSSON; M.KROOK; S.ATRIAN; R.GONZALEZ-DUARTE; J.JEFFERY; D.GHOSH BIOCHEMISTRY vol. 34, 1995, pages 6003 - 6013
IKE ET AL. NUCLEIC ACIDS RES. vol. 11, 1983, page 477
ITAKURA ET AL. ANNU. REV. BIOCHEM. vol. 53, 1984, page 323
ITAKURA ET AL. SCIENCE vol. 198, 1984, page 1056
J. ORG. CHEM. vol. 55, 1990, pages 812 - 815
K.M.BOHREN; B.BULLOCK; B.WERMUTH; K.H.GABBAY J.BIOL. CHEM. vol. 264, 1989, pages 9547 - 9551
LACERDA ET AL. TETRAHEDRON: ASYMMETRY vol. 17, 2006, pages 1186 - 1188
NARANG, S.A. TETRAHEDRON vol. 39, 1983, page 3
PEARSON; LIPMAN PROC. NATL. ACAD, SCI. (USA) vol. 85, no. 8, 1988, pages 2444 - 2448
SIMON ET AL. ANGEW. CHEMIE vol. 97, 1985, page 541
THOMAS, K.R.; CAPECCHI, M.R. CELL vol. 51, 1987, page 503
U.OPPERMANN; C.FILLING; M.HULT; N.SHAFQAT; X.Q.WU; M.LINDH; J.SHAFQAT; E.NORDLING; Y.KALLBERG; B.PERSSON CHEMICO-BIOLOGICAL INTERACTIONS vol. 143, 2003, pages 247 - 253
W. HUMMEL; K. ABOKITSE; K. DRAUZ; C. ROLLMANN; H. GROGER ADV. SYNTH. CATAL. vol. 345, no. 1 + 2, 2003, pages 153 - 159
YANAGISAWA, H.; ISHIHARA, S.; ANDO, A.; KANAZAKI, T.; MIYAMOTO, S. ET AL. J. MED. CHEM. vol. 30, 1987, page 11

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9758500B2 (en) 2012-04-16 2017-09-12 Basf Se Process for the preparation of (3E, 7E)-homofarnesol
CN110555138A (zh) * 2019-08-05 2019-12-10 慧镕电子系统工程股份有限公司 一种云计算架构下的混合云存储方法
CN110555138B (zh) * 2019-08-05 2022-09-13 慧镕电子系统工程股份有限公司 一种云计算架构下的混合云存储方法

Also Published As

Publication number Publication date
WO2011009849A3 (fr) 2011-04-07
TW201109441A (en) 2011-03-16

Similar Documents

Publication Publication Date Title
JP5101510B2 (ja) 新規デヒドロゲナーゼ、その誘導体および光学活性アルカノールの製造方法
US11634743B2 (en) Coupled, self-sufficient biotransformation of chenodeoxcholic acid to ursodeoxycholic acid and novel enzyme mutants applicable in said process
JP6126634B2 (ja) アロマトレウム・アロマチカムＥｂＮ１（アゾアルカス・エスピーＥｂＮ１）のアルコールデヒドロゲナーゼを用いたＬ−フェニレフリンの製造方法
Bechtold et al. Biotechnological development of a practical synthesis of ethyl (S)-2-ethoxy-3-(p-methoxyphenyl) propanoate (EEHP): over 100-fold productivity increase from yeast whole cells to recombinant isolated enzymes
Chen et al. Multi‐Enzymatic Biosynthesis of Chiral β‐Hydroxy Nitriles through Co‐Expression of Oxidoreductase and Halohydrin Dehalogenase
US8338146B2 (en) Method for producing optically active alcohols using an Azoarcus sp. EbN1 dehydrogenase
Wu et al. Enzymatic preparation of t-butyl-6-cyano-(3R, 5R)-dihydroxyhexanoate by a whole-cell biocatalyst co-expressing carbonyl reductase and glucose dehydrogenase
US7465842B2 (en) Enantioselective biotransformation for preparation of protein tyrosine kinase inhibitor intermediates
Richter et al. Biochemical characterisation of a NADPH-dependent carbonyl reductase from Neurospora crassa reducing α-and β-keto esters
US20060211099A1 (en) L-carnitin dehydrogenases, their derivatives and method for producing substituted (s) alkanols
WO2011009849A2 (fr) Procédé pour la préparation d'esters d'hydroxyacides optiquement actifs
JP2009520483A (ja) 光学活性アルコールを製造するための酵素的還元
CA2753634C (fr) Procede de reduction enzymatique stereoselective de composes ceto
JP4926975B2 (ja) 光学活性アルコールの製造方法
US8658400B2 (en) Biocatalysts for manufacturing duloxetine alcohol
Xue et al. Highly efficient deracemization of racemic 2-hydroxy acids in a three-enzyme co-expression system using a novel ketoacid reductase
US20120135476A1 (en) Process for preparing n-heterocyclic optically active alcohols
Richter et al. 5 CONSTRUCTION OF A WHOLE-CELL CATALYST FOR THE PRODUCTION OF L-GLYCERALDEHYDE

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10737845

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10737845

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载